Abstract
Venous thromboembolism (VTE) is a major public health issue, with a high incidence in hospitalised patients. Furthermore, many VTE events are preventable with appropriate thromboprophylaxis. Medical thromboprophylaxis usually comprises heparins, while warfarin has been the mainstay of long term anticoagulation for many years. Both drugs are limited by their narrow therapeutic index and the need for regular monitoring. The introduction of low molecular weight heparins and fondaparinux has overcome some of these shortfalls but their use remains restricted by requisite parenteral administration. There is a clear need for new anticoagulants with predictable pharmacokinetics and anticoagulant effect. To this end, 2 new agents; dabigatran and rivaroxaban, have recently been licensed for use in orthopaedic thromboprophylaxis. This review discusses the limitations of traditional anticoagulants, and summarises the development and clinical studies pertaining to the use of 3 new targeted anticoagulants: idraparinux, rivaroxaban and dabigatran in VTE, in addition to the limitations of these novel agents.
Keywords: Venous thromboembolism, thromboprophylaxis, anticoagulation, idraparinux, rivaroxaban, dabigatran
Current Vascular Pharmacology
Title: New Anticoagulants for Prevention and Treatment of Venous Thromboembolism
Volume: 8 Issue: 3
Author(s): Lara N. Roberts and Roopen Arya
Affiliation:
Keywords: Venous thromboembolism, thromboprophylaxis, anticoagulation, idraparinux, rivaroxaban, dabigatran
Abstract: Venous thromboembolism (VTE) is a major public health issue, with a high incidence in hospitalised patients. Furthermore, many VTE events are preventable with appropriate thromboprophylaxis. Medical thromboprophylaxis usually comprises heparins, while warfarin has been the mainstay of long term anticoagulation for many years. Both drugs are limited by their narrow therapeutic index and the need for regular monitoring. The introduction of low molecular weight heparins and fondaparinux has overcome some of these shortfalls but their use remains restricted by requisite parenteral administration. There is a clear need for new anticoagulants with predictable pharmacokinetics and anticoagulant effect. To this end, 2 new agents; dabigatran and rivaroxaban, have recently been licensed for use in orthopaedic thromboprophylaxis. This review discusses the limitations of traditional anticoagulants, and summarises the development and clinical studies pertaining to the use of 3 new targeted anticoagulants: idraparinux, rivaroxaban and dabigatran in VTE, in addition to the limitations of these novel agents.
Export Options
About this article
Cite this article as:
N. Roberts Lara and Arya Roopen, New Anticoagulants for Prevention and Treatment of Venous Thromboembolism, Current Vascular Pharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157016110791112232
DOI https://dx.doi.org/10.2174/157016110791112232 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patents of Pentoxifylline Administration on Some Diseases and Chronic Wounds
Recent Patents on Regenerative Medicine Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Implications of Pharmacogenetics for Oral Anticoagulants Metabolism
Current Drug Metabolism Sex Differences in Oxidative Stress Biomarkers
Current Drug Targets Targeted Drug Delivery: Trends and Perspectives
Current Drug Delivery COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases
Current Cancer Drug Targets Appraisal of Saxagliptin as Treatment of Type 2 Diabetes
Current Drug Therapy In Vivo Measurement in Pigs of Wash-In Kinetics of Xenon at its Site of Action
Current Clinical Pharmacology Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Infectious Disorders - Drug Targets Diminished Sphenous Compartment Connective Tissue Elasticity has Little Impact on Low Grade Venous Insufficiency: An Ultrasound Shearwave Elastography Study
Current Medical Imaging Obstructive Jaundice does not Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery
Current Drug Delivery Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Medical Management and Risk Reduction of the Cardiovascular Effects of Underwater Diving
Current Vascular Pharmacology Low Estimated Glomerular Filtration Rate is Associated with High Recurrence Rate and Poor Prognosis of Hemorrhage Stroke
Current Neurovascular Research Nutritional Iron Deficiency: The Role of Oral Iron Supplementation
Current Medicinal Chemistry Medicinal Chemistry of Antimigraine Drugs
Current Medicinal Chemistry Portal Vein Embolization: A Preoperative Approach to Improve the Safety of Major Hepatic Resection
Current Medical Imaging Deep Neck Infections
Infectious Disorders - Drug Targets